Scarica l'app Stockscreener
13.15
2.45%
-0.33
Dopo l'orario di chiusura:
13.15
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
TRDA PE Ratio & Valuation, Is TRDA Overvalued - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock - MarketBeat
Insider Sell Alert: Kory Wentworth Sells Shares of Entrada Thera - GuruFocus
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com - Investing.com Canada
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock - Investing.com
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
(TRDA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TRDA (NASDAQ: TRDA) insider 10b5‑1 sales listed, 11,388-share trade noted - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Cantor Fitzgerald Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-03-31 23:31:11 - baoquankhu1.vn
Risk Analysis: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc still a buy after recent gains2026 Retail & Capital Efficient Trade Techniques - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Big Picture: Can Entrada Therapeutics Inc deliver consistent EPS growthTrade Analysis Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
Hedge Fund Bets: Can Entrada Therapeutics Inc outperform under higher oil prices2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA) - Stock Titan
Responsive Playbooks and the TRDA Inflection - Stock Traders Daily
Gainers Report: Can Entrada Therapeutics Inc ride the EV wave2026 Sector Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc benefiting from innovation trends2026 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug EndMonth: How does Entrada Therapeutics Inc compare to its peersPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Trading Recap: Will Entrada Therapeutics Inc benefit from rising consumer demandGlobal Markets & Verified Momentum Stock Watchlist - baoquankhu1.vn
Harmony Biosciences (NASDAQ:HRMY) and Entrada Therapeutics (NASDAQ:TRDA) Critical Review - Defense World
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) COO Sells 3,116 Shares of Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 11,388 Shares - MarketBeat
Understanding the Setup: (TRDA) and Scalable Risk - Stock Traders Daily
Entrada Therapeutics (NASDAQ:TRDA) Hits New 1-Year HighTime to Buy? - MarketBeat
[144] Entrada Therapeutics, Inc. SEC Filing - Stock Titan
Aug Breakouts: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Gainers & Entry Point Confirmation Alerts - baoquankhu1.vn
Aug Volume: How does Entrada Therapeutics Inc compare to its peersJuly 2025 Final Week & Precise Buy Zone Identification - baoquankhu1.vn
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kory James Wentworth Sells 7,988 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Entrada Therapeutics (TRDA) CFO executes planned stock sale - Stock Titan
Royce & Associates LP Raises Stock Position in Entrada Therapeutics, Inc. $TRDA - MarketBeat
HC Wainwright Has Optimistic Outlook of TRDA Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for TRDA Earnings - MarketBeat
TRDA SEC FilingsEntrada Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Form 144: TRDA insider sales — Kory Wentworth sold 8,651 shares (TRDA) - Stock Titan
TRDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales - Stock Titan
Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales - Stock Titan
Entrada Therapeutics (TRDA) COO logs new RSU, option grants and tax share disposals - Stock Titan
Entrada Therapeutics (TRDA) grants RSUs and options as automatic share sales cover taxes - Stock Titan
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants - National Today
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
The Technical Signals Behind (TRDA) That Institutions Follow - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Crescent Biopharma (CBIO) - The Globe and Mail
Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
TRDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Entrada Therapeutics (TRDA) Quarterly Revenue Slump Tests Bullish Growth Narratives - simplywall.st
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Beats Estimates By $0.38 EPS - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 54% Potential Upside - DirectorsTalk Interviews
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TRDAForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Entrada Therapeutics Q4 net loss and EPS beat expectations - TradingView
Earnings Summary: Entrada Therapeutics Q4 - Benzinga
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):